video (2:39 min)
Posted on : 08/17/16
Description: Jonathan Ledermann, MD, FRCP from University College
London, London, UK discusses his presentation on the update on the
results of the Study 19 trial (NCT00753545). Study 19 was a randomized
maintenance trial using olaparib in patients with recurrent high grade
serous ovarian cancer, who had previously responded to platinum-based
chemotherapy. Patients were randomized to olaparib or a placebo. Prof.
Ledermann talks about the 3 year follow-up on overall surviva (OS) and
how there was meaningful improvement in patients taking olaparib. These
findings, however, were not statistically significant. Prof. Ledermann
further discusses how the trial looked into several supplementary
exploratory endpoints to support the clinical value of the difference in
OS of 4.7 months that was found. Endpoints looked at were: time to
first subsequent treatment and time to second subsequent treatment.
Prof. Ledermann discusses the importance of olaparib to OS rates.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting
held in Chicago, IL.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.